Oruka Therapeutics’ (ORKA) Outperform Rating Reiterated at Wedbush

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “outperform” rating reaffirmed by analysts at Wedbush in a research report issued to clients and investors on Tuesday,RTT News reports. They currently have a $40.00 target price on the stock. Wedbush’s price objective would indicate a potential upside of 83.65% from the company’s previous close. Wedbush also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.36) EPS, FY2024 earnings at ($2.46) EPS, Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.74) EPS, FY2026 earnings at ($2.08) EPS, FY2027 earnings at ($2.45) EPS and FY2028 earnings at ($2.94) EPS.

A number of other equities research analysts also recently weighed in on ORKA. HC Wainwright reissued a “buy” rating and set a $45.00 target price on shares of Oruka Therapeutics in a research report on Thursday, October 31st. Stifel Nicolaus began coverage on shares of Oruka Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $49.00 price target on the stock. Leerink Partnrs raised shares of Oruka Therapeutics to a “strong-buy” rating in a report on Tuesday, September 17th. TD Cowen initiated coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They issued a “buy” rating on the stock. Finally, Jefferies Financial Group started coverage on Oruka Therapeutics in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $43.17.

Oruka Therapeutics Price Performance

Shares of ORKA traded up $0.65 during mid-day trading on Tuesday, hitting $21.78. The company’s stock had a trading volume of 118,512 shares, compared to its average volume of 64,078. Oruka Therapeutics has a one year low of $18.72 and a one year high of $53.88. The business has a 50-day moving average of $26.62. The firm has a market capitalization of $26.35 million, a price-to-earnings ratio of -3.41 and a beta of 0.87.

Hedge Funds Weigh In On Oruka Therapeutics

Large investors have recently modified their holdings of the business. FMR LLC bought a new stake in shares of Oruka Therapeutics during the 3rd quarter worth approximately $114,763,000. RTW Investments LP bought a new position in shares of Oruka Therapeutics in the third quarter valued at $45,359,000. Braidwell LP acquired a new position in Oruka Therapeutics during the third quarter worth $12,640,000. Great Point Partners LLC bought a new stake in Oruka Therapeutics during the third quarter worth $12,614,000. Finally, Point72 Asset Management L.P. bought a new stake in Oruka Therapeutics during the third quarter worth $11,822,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.